pBFS Guided rTMS Treating Mild Alzheimer's Disease(AD)

Status Recruiting

Clinical Trial Summary

This study aims to investigate the effectiveness and safety of rTMS treatment under the guidance of personalized Brain Functional Sectors (pBFS) for the cognitive ability of patients with mild Alzheimer's disease.

Clinical Trial Description

Alzheimer's Disease (AD) is a neurodegenerative disorder characterized by memory impairment and cognitive decline. Personalized brain functional sectors (pBFS) using resting-state functional MRI scans have shown promise in precisely identifying individualized brain function networks. In this study, we aim to select tailored stimulation sites within the working memory network (WMN) or the default mode network (DMN) as intervention targets for mild AD patients using pBFS. To evaluate the effectiveness and safety of this intervention, participants will be randomized into four groups: active repetitive transcranial magnetic stimulation (rTMS) to the WMN group, active rTMS to the DMN group, and sham rTMS to either the WMN or DMN group at a ratio of 2:2:1:1. Each participant will receive 3600 pulse active or sham rTMS in each session, consisting of two 1800 pulse treatments with a 50-minute break in between. Two separate treatment sessions will be administered daily, resulting in a sum of 7200 pulses per day. The intervention will be administered for 15 continuous days. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05872243
Study type	Interventional
Source	Changping Laboratory
Contact	Na Xu, Ph.D.
Phone	+8618810069676
Email	naxu@cpl.ac.cn
Status	Recruiting
Phase	N/A
Start date	September 11, 2023
Completion date	August 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00243451` - Early Detection of Mild Cognitive Impairment in Individual Patients	N/A
Recruiting	`NCT05417555` - Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease	N/A
Terminated	`NCT01482013` - Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease	Phase 1
Completed	`NCT03186989` - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease	Phase 1/Phase 2
Not yet recruiting	`NCT03752294` - A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.	Phase 1
Completed	`NCT01013610` - An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease	Phase 1
Recruiting	`NCT06058234` - Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
Active, not recruiting	`NCT03234686` - Deferiprone to Delay Dementia (The 3D Study)	Phase 2
Completed	`NCT05233774` - Lomecel-B Effects on Alzheimer's Disease	Phase 2
Terminated	`NCT00582855` - Effect of AQW051 in Patients With Memory Impairment	Phase 2
Completed	`NCT01061489` - Sensory-cognitive and Physical Fitness Training in Mild Cognitive Impairment	N/A
Completed	`NCT01548287` - A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment	Phase 2
Terminated	`NCT00706186` - Safety and Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients	Phase 4